Effect of tiagabine and topiramate on porphyrin metabolism in an in vivo model of porphyria

Pharmacology and Toxicology

Volumn 89, Issue 1, 2001, Pages 15-22

  Krijt, Jan ^a   Krijtová, Hana ^a   Sanitrák, Jaroslav ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; OXADIAZON; PENTOXYRESORUFIN DEALKYLASE; PHENOBARBITAL; PORPHOBILINOGEN; PORPHYRIN; TIAGABINE; TOPIRAMATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOSYNTHESIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; ENZYME ACTIVITY; MALE; NONHUMAN; PORPHYRIA; PORPHYRIN METABOLISM; PRIORITY JOURNAL; RAT; URINARY EXCRETION;

ANIMALIA; RATTUS NORVEGICUS;

EID: 0034919396     PISSN: 09019928     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0773.2001.d01-130.x     Document Type: Article

References (37)

1. Aitio, A: A simple and sensitive assay of 7-ethoxycoumarin deethylation. Analyt. Biochem. 1978, 85, 488-491.
2. Blekkenhorst, G. H., G. G. Harrison, E. S. Cook & L. Eales: Screening of certain anaesthetic agents for their ability to elicit acute porphyric phases in susceptible patients. Brit. J. Anaest. 1980, 52, 759-762.
3. Bonkovsky, H. L., J. F. Healey, P. R. Sinclair & J. F. Sinclair: Conversion of 5-aminolevulinate into haem by homogenates of human liver. Biochem. J. 1985, 227, 893-901.
4. Bonkowsky, H. L., P. R. Sinclair, S. Emery & J. F. Sinclair: Seizure management in acute hepatic porphyria: risks of valproate and clonazepam. Neurology 1980, 30, 588-592.
5. Bohrer, H., H. Schmidt, E. Martin, R. Lux, K. Bolsen & G. Goerz: Testing the porphyrinogenicity of profolol in a primed rat model. Brit. J. Anaesth. 1995, 75, 334-338.
6. Day, R. S., G. H. Blekkenhorst & L. Eales: Hepatic porphyrins in variegate porphyria. New Engl. J. Med. 1980, 303, 1368-1369.
7. Day, R. S., L. Eales & P. B. Disler: Porphyrias and the kidney. Nephron 1981, 28, 261-267.
8. Elder, G. H., R. J. Hift & P. N. Meissner: The acute porphyrias. Lancet 1997, 349, 1613-1617.
9. Elwes, R. D. & C. D. Binnie: Clinical pharmacokinetics of newer antiepileptic drugs. Lamotrigine, vigabatrin, gabapentin and oxcarbazepine. Clin. Pharmacokin. 1996, 30, 403-415.
10. Goerz, G, K. Bolsen, H. Bohrer, C. Fritsch, K. Kalka & K. L. Rominger: Effects of clonidine in a primed rat model of acute hepatic porphyria. Arzneimittelforsch. 1997, 47, 731-733.
11. Hahn, M., O. S. Gildemeister, G. L. Krauss, J. A. Pepe, R. W. Lambrecht, S. Donohue & H. L. Bonkovsky: Effects of new anticonvulsant medications on porphyrin synthesis in cultured liver cells: potential implications for patients with acute porphyria. Neurology 1997, 49, 97-106.
12. Handschin, C. & U. A. Meyer: A conserved nuclear receptor consensus sequence (DR-4) mediates transcriptional activation of the chicken CYP2H1 gene by phenobarbital in a hepatoma cell line. J. Biol. Chem. 2000, 275, 13362-13369.
13. Jover, R., K. Hoffmann & U. A. Meyer: Induction of 5-aminolevulinate synthase by drugs is independent of increased apocytochrome P450 synthesis. Biochem. Biophys. Res. Commun. 1996, 226, 152-157.
14. Kappas, A., S. Sassa, R. A. Galbraith & Y. Nordmann: The porphyrias. In: The metabolic and molecular basis of inherited disease. Eds.: C. R. Scriver, A. L. Beandet, W. S. Sly & D. Valle. McGraw-Hill, New York, NY, USA, 1995, pp. 2103-2159.
15. Kirsch, R. E., P. N. Meissner & R. J. Hift: Variegate porphyria. Seminars in Liver Disease 1998, 18, 33-41.
16. Kolluri, S., K. K. Elbirt & H. L. Bonkovsky: Heme biosynthesis in a chicken hepatoma cell line (LMH): comparison with primary chick embryo liver cells (CELC). Biochim. Biophys. Acta 1999, 1472, 658-667.
17. Krijt, J., P. Stránská, P. Maruna, M. Vokurka & J. Sanitrák: Herbicide-induced experimental variegate porphyria in mice: tissue porphyrinogen accumulation and response to porphyrogenic drugs. Can. J. Physiol. Pharmacol. 1997, 75, 1181-1187.
18. Lambrecht, R. W., O. S. Gildemeister, A. Williams, J. A. Pepe, K. D. Tortorelli & H. L. Bonkovsky: Effects of selected antihypertensives and analgesics on hepatic porphyrin accumulation: implications for clinical porphyria. Biochem. Pharmacol. 1999, 58, 887-896.
19. Lindberg, R. L. P., C. Porcher, B. Grandchamp, B. Ledermann, K. Bürki, S. Brandner, A. Aguzzi & U. A. Meyer: Porphobilinogen deaminase deficiency in mice causes a neuropathy resembling that of human hepatic porphyria. Nature Genetics 1996, 12, 195-199.
20. Marver, H. S., D. P. Tschudy, M. G. Perloth, A. Collins & G. Hunter: The determination of aminoketones in biological fluids. Analyt. Biochem. 1966, 14, 53-60.
21. Matringe, M., J. M. Camadro, P. Labbe & R. Scalla: Protoporphyrinogen oxidase inhibition by three peroxidizing herbicides: Oxadiazon, LS-82-556 and M&B 39279. FEBS Letters 1989, 245, 35-38.
22. McGuire, G. M., G. J. A. Macphee, G. G. Thompson, B. K. Park, M. R. Moore & M. J. Brodie: The effects of chronic carbamazepine treatment on haem biosynthesis in man and rat. Eur. J. Clin. Pharmacol. 1988, 35, 241-247.
23. Medlock, A. E., B. Davidson, P. M. Meissner & H. A. Dailey: A South-African (R59W) variegate porphyria mouse. In: Millenium meeting on porphyrins and porphyrias. Paris, 2000, p. 19 (abstract).
24. Meissner, P., P. Adams & R. Kirsch: Allosteric inhibition of human lymphoblast and purified porphobilinogen deaminase by protoporphyrinogen and coproporphyrinogen. A possible mechanism for the acute attack of variegate porphyria. J. Clin. Invest. 1993, 91, 1436-1444.
25. Moore, M. R., K. E. L. McColl, C. Rimington & A. Goldberg: Pathogenesis of the neuropathy of acute porphyrias. In: Disorders of porphyrin metabolism. Plenum Publishing Corporation, New York, NY, USA, 1987, pp. 119-137.
26. Ponka, P.: Tissue-specific regulation of iron metabolism and heme synthesis: distinct control mechanisms in erythroid cells. Blood 1997, 89, 1-25.
27. Radulovic, L. L., D. Turck, A. von Hodenberg, K. O. Vollmer, W. P. McNally, P. D. DeHart, B. J. Hanson, H. N. Bockbrader & T. Chang: Disposition of gabapentin (neurontin) in mice, rats, dogs, and monkeys. Drug Metab. Disp. 1995, 23, 441-448.
28. Regnaud, L., G. Sirois & S. Chakrabarti: Effect of four-day treatment with carbamazepine at different dose levels on microsomal enzyme induction, drug metabolism and drug toxicity. Pharmacology & Toxicology 1988, 62, 3-6.
29. Rimington, C. & R. Ziegler: Experimental porphyria in rats induced by chlorinated benzenes. Biochem. Pharmacol. 1963, 12, 1387-1397.
30. Rutten, A. A. J. J. L., H. E. Falke, J. F. Catsburg, H. M. Wortelboer, B. J. Blaauboer, L. Doorn, F. X. R. van Leeuwen, R. Theelen & I. M. C. M. Rietjens: Interlaboratory comparison of microsomal ethoxyresorufin and pentoxyresorufin O-dealkylation determinations: standardization of assay conditions. Arch. Toxicol. 1992, 66, 237-244.
31. Salonpää, P., K. Krause, O. Pelkonen & H. Raunio: Up-regulation of CYP2A5 expression by porphyrogenic agents in mouse liver. Naunyn-Schmiedeberg's Arch. Pharmacol. 1995, 351, 446-452.
32. Tatum, W. O. IV & S. B. Zachariah: Gabapentin treatment of seizures in acute intermittent porphyria. Neurology 1995, 45, 1216-1217.
33. Tokola, O., I. B. Linden & R. Tenhunen: The effects of haem arginate and haematin upon the allylisopropylacetamide induced experimental porphyria in rats. Pharmacology & Toxicology 1987, 61, 75-78.
34. Wakabayashi, K. & P. Böger: General physiological characteristics and mode of action of peroxidizing herbicides. In: Peroxidizing herbicides. Eds.: K. Wakabayashi & P. Böger. Springer-Verlag, Berlin-Heidelberg, 1999, pp. 163-190.
35. Yandel, M. L. & M. R. Watters: Treatment of complex partial status epilepticus unmasking acute intermittent porphyria in a patient with resected anaplastic glioma. Clin. Neurol. Neurosurg. 1995, 97, 261-263.
36. Zadra, M., R. Grandi, L. C. Erli, D. Mirabile & A. Brambilla: Treatment of seizures in acute intermittent porphyria: safety and efficacy of gabapentin. Seizure 1998, 7, 415-416.
37. Zimmer, S., H. Taub & G. S. Marks: A comparison of the porphyrin-inducing activity of barbiturates and benzodiazepines in chick embryo liver cells. Can. J. Physiol. Pharmacol. 1980, 58, 991-995.